NASDAQ:ACSTAcasti Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acasti Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.65 +0.01 (+1.57 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$0.63Now: $0.65▼$0.6550-Day Range$0.39MA: $0.60▼$0.6852-Week Range$0.25Now: $0.65▼$3.08Volume419,329 shsAverage Volume2.65 million shsMarket Capitalization$58.41 millionP/E RatioN/ADividend YieldN/ABeta2.11 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAcasti Pharma has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.19, Acasti Pharma has a potential upside of 547.4% from its current price of $0.65.Amount of Analyst CoverageAcasti Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAcasti Pharma has received 281 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcasti Pharma has received 242 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcasti Pharma has received 53.73% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote “Outperform” if you believe ACST will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.78% of the stock of Acasti Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from ($0.34) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcasti Pharma has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACST Previous Symbol CUSIPN/A CIK1444192 Webwww.acastipharma.com Phone45-0687-2262Debt Debt-to-Equity RatioN/A Current Ratio2.07 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book4.63Profitability EPS (Most Recent Fiscal Year)($0.71) Net Income$-39,290,000.00 Net MarginsN/A Return on Equity-2,168.55% Return on Assets-128.83%Miscellaneous Employees28 Outstanding Shares90,209,000Market Cap$58.41 million Next Earnings Date6/24/2020 (Estimated) OptionableNot Optionable NASDAQ:ACST Rates by TradingView Receive ACST News and Ratings via Email Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions How has Acasti Pharma's stock been impacted by COVID-19 (Coronavirus)? Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACST stock has increased by 68.2% and is now trading at $0.6475. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Acasti Pharma? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acasti Pharma. When is Acasti Pharma's next earnings date? Acasti Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, June 24th 2020. View our earnings forecast for Acasti Pharma. How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc (NASDAQ:ACST) released its quarterly earnings results on Tuesday, January, 15th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. View Acasti Pharma's earnings history. What price target have analysts set for ACST? 6 Wall Street analysts have issued 1 year price objectives for Acasti Pharma's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Acasti Pharma's share price to reach $4.19 in the next twelve months. This suggests a possible upside of 547.4% from the stock's current price. View analysts' price targets for Acasti Pharma. What are Wall Street analysts saying about Acasti Pharma stock? Here are some recent quotes from research analysts about Acasti Pharma stock: 1. According to Zacks Investment Research, "Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada. " (2/20/2020) 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $4.96/share, as a 25x multiple of taxed and diluted 2030 EPS of $1.23 discounted back to FY 2020 at 20%; and (b) an NPV discounted cash flow between FY 2020-2030 of $6.32/share, with a discount rate of 13% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/15/2019) Has Acasti Pharma been receiving favorable news coverage? Media headlines about ACST stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acasti Pharma earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAcasti Pharma. Are investors shorting Acasti Pharma? Acasti Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 478,400 shares, an increase of 48.5% from the April 30th total of 322,100 shares. Based on an average trading volume of 1,810,000 shares, the short-interest ratio is currently 0.3 days. Approximately 0.6% of the company's shares are sold short. View Acasti Pharma's Current Options Chain. Who are some of Acasti Pharma's key competitors? Some companies that are related to Acasti Pharma include Marinus Pharmaceuticals (MRNS), XOMA (XOMA), Inflarx (IFRX), Iterum Therapeutics (NRBO), LifeVantage (LFVN), OptiNose (OPTN), Gemphire Therapeutics (GEMP), IDEAYA Biosciences (IDYA), Lexicon Pharmaceuticals (LXRX), Aravive (ARAV), NuCana (NCNA), IVERIC bio (ISEE), Kalvista Pharmaceuticals (KALV), Paratek Pharmaceuticals (PRTK) and Chimerix (CMRX). View all competitors. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Outlook Therapeutics (OTLK), Amarin (AMRN), Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Seanergy Maritime (SHIP), Abraxas Petroleum (AXAS), Unum Therapeutics (UMRX), Polarityte (PTE), Amplify Energy (AMPY) and Amplify Energy (AMPY). Who are Acasti Pharma's key executives? Acasti Pharma's management team includes the following people: Ms. Janelle D' Alvise, Pres, CEO, Corp. Sec. & DirectorDr. Pierre Lemieux, Co-Founder and COO & Chief Scientific OfficerMr. Jean-François Boily, VP of Fin.Mr. Brian James Groch, Chief Commercial Officer (Age 53) What is Acasti Pharma's stock symbol? Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST." Who are Acasti Pharma's major shareholders? Acasti Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Oppenheimer & Co. Inc. (0.22%) and Morgan Stanley (0.18%). View institutional ownership trends for Acasti Pharma. Which institutional investors are selling Acasti Pharma stock? ACST stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Acasti Pharma. Which institutional investors are buying Acasti Pharma stock? ACST stock was acquired by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc.. View insider buying and selling activity for Acasti Pharma. How do I buy shares of Acasti Pharma? Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acasti Pharma's stock price today? One share of ACST stock can currently be purchased for approximately $0.65. How big of a company is Acasti Pharma? Acasti Pharma has a market capitalization of $58.41 million. The biopharmaceutical company earns $-39,290,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. Acasti Pharma employs 28 workers across the globe. What is Acasti Pharma's official website? The official website for Acasti Pharma is www.acastipharma.com. How can I contact Acasti Pharma? Acasti Pharma's mailing address is 545 Promenade du Centropolis Suite 100, Laval A8, H7T 0A3. The biopharmaceutical company can be reached via phone at 45-0687-2262 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
